Longwood Fund — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more
Anuncia Medical develops the ReFlow Ventricular System, an implantable device that lets patients or caregivers non-invasively flush a shunt catheter to help manage hydrocephalus, including in pediatric patients.
BiotechHealthtechMedical DevicesScottsdale, US
Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)
BoardEdgar D Janotta(Director)Stanton Rowe(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
Co-investorsXcellerant Ventures
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)NIGEL CROCKETT(Executive Officer)NICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)MICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalSR One Capital ManagementSV Health InvestorsVertex Ventures HC
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalBiotechnology Value FundCatalio Capital Management+2 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersMission BiocapitalDolby Family VenturesForbionService Provider Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.